by Aptamers are short, single-stranded DNA or RNA oligonucleotides that are selected through an in vitro selection process called SELEX. Aptamers show high affinity and specificity for molecular recognition of targets ranging from small molecules to proteins and cells. They have advantages over antibodies such as ease of production, low immunogenicity, and suitability for use at higher temperatures. The aptamer market finds widespread applications in research, diagnostics, therapeutics and other areas due to their properties.
The Global Aptamers Market is estimated to be valued at US$ 7217.85 Mn in 2024 and is expected to exhibit a CAGR of 11% over the forecast period 2024 to 2031.
Key Takeaways
Key players: Key players operating in the aptamers market are ZOLL Medical Corporation, Stryker, Brunswick MedTech, Michigan Instruments, SunLife Sciences Pvt Ltd., CPR Medical Devices, Inc., Medtronic, Faith Group, Nihon Kohden Corporation, SCHILLER Americas Inc.
Key opportunities: Rising healthcare expenditure is opening up opportunities for technology advancement and adoption of novel diagnostic and therapeutic agents like aptamers. Increased R&D efforts for development of aptamers against new targets is another growth opportunity.
Global expansion: North America dominates the Aptamers Market Size due to strong government support and investment in healthcare innovation. However, Asia Pacific region is expected to witness highest growth owing to growing pharmaceutical industry, healthcare funding and patient pool in the region. Key players are also expanding their presence in emerging markets of Asia Pacific and Latin America.
Market drivers:
Rising healthcare expenditure across major economies is one of the key drivers for the aptamers market. Higher healthcare spending is enabling adoption of advanced technologies like aptamers for diagnosis and treatment. Growth in biopharmaceutical industry and increased focus on precision medicine are also fueling demand of aptamers.
PEST Analysis
Political: The market is positively impacted by supportive government policies and regulations for research and development in life sciences and healthcare industry. Most of the major market players conform to guidelines set by regulatory bodies like FDA that ensure quality standards.
Economic: Growing biotechnology and pharmaceutical industries have boosted research and development activities incorporating aptamer-based technologies and diagnostics. This is driving consumption and demand for aptamers. Increasing healthcare spending also benefits market growth.
Social: Aging population and growing incidence of chronic diseases increases the need for accurate diagnostics, targeted therapeutics and personalized medicine. Aptamers are increasingly finding applications in these areas to fulfill unmet needs. Growing health awareness in society promotes their adoption.
Technological: Aptamers provide benefits over antibodies like inexpensive production through chemical synthesis, high stability during storage and ease of modification for new functionalities. Their discovery has enabled the development of molecular diagnostic tools, biosensors, targeted drug delivery technologies and novel therapeutics. Advancements in selection and screening technologies have enhanced the aptamer identification process.
North America holds the major share in the aptamers market in terms of value owing to large biotechnology and pharmaceutical industries, availability of latest technologies, infrastructure and higher spending on healthcare and research. The United States accounts for the largest regional market.
The Asia Pacific region is poised to be the fastest growing market for aptamers during the forecast period on account of rising healthcare expenditure, expanding biomedical sectors, growing public and private research funding and increasing investment by leading market players in the emerging countries of China, India and Japan.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
